The Effect of Diflunisal on Familial Amyloidosis
Familial Amyloid Polyneuropathy, Familial Amyloidosis
About this trial
This is an interventional treatment trial for Familial Amyloid Polyneuropathy focused on measuring familial amyloid polyneuropathy, familial amyloidosis, diflunisal, amyloidosis, transthyretin, peripheral neuropathy, autonomic neuropathy, amyloid cardiomyopathy
Eligibility Criteria
Inclusion Criteria: Age 18 to 75 years Biopsy proven amyloidosis Genotyping of variant transthyretin Signs of peripheral or autonomic neuropathy Exclusion Criteria: Use of other non-steroidal anti-inflammatory drugs Other causes of sensorimotor polyneuropathy Anticipated survival <2 years or liver transplantation in <1 yr Liver transplantation Profound nerve, heart or kidney impairment Pregnancy or unwillingness to use contraception by women of childbearing age Active or recent gastrointestinal bleeding Non-steroidal or aspirin drug allergy/hypersensitivity
Sites / Locations
- Amyloidosis Center, Boston Medical Center
- Mayo Clinic Rochester
- Mount Sinai School of Medicine, Department of Medicine
- IRCCS Policlinico San Matteo
- Kumamoto University
- Shinshu University
- Umea University Hospital
- King's College Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Diflunisal
Placebo
Diflunisal 250 mg po bid
Placebo 1 po bid